| Old Articles: <Older 7221-7230 Newer> |
|---|
 |
The Motley Fool
March 2, 2011
Brian Orelli |
When Will Dendreon Make Money? Not for awhile ... it's a biotech thing.   |
The Motley Fool
March 2, 2011
Susmita Chatterjee |
How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others? |
The Motley Fool
March 1, 2011
Brian Orelli |
Uncle Sam Gives Novavax a Big Hand Up Cash is everything for a development-stage drugmaker. |
The Motley Fool
March 1, 2011
David Williamson |
Glaxo Gets Its Day in Court GlaxoSmithKline and Rite-Aid are taking Abbott's HIV drug pricing to the courts. |
Chemistry World
March 2011
Bea Perks |
Editorial: At the forefront The news that most of Pfizer's 2400 employees at Sandwich, U.K. will be made redundant over the next two years was met with surprise, disappointment and anger. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
February 28, 2011
Brian Orelli |
Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
| <Older 7221-7230 Newer> Return to current articles. |
